Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1/2 dose-escalation study of intrathecal AstroRx in ALS
MOH_2018-03-13_002186Phase 2Active, not recruiting
- Sponsor
- Kadimastem
- Start
- Jun 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of AstroRx in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Kadimastem. Primary endpoint: Safety and tolerability of AstroRx. Started Jun 2017; status: active, not recruiting.
02
Drugs
AstroRx
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on MOH_2018-03-13_002186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-03-13_002186.